Department of Pharmacy, University of Salerno, 84084 Fisciano, Italy.
PhD Program in Drug Discovery & Development at University of Salerno, 84084 Fisciano, Italy.
Int J Mol Sci. 2022 May 11;23(10):5354. doi: 10.3390/ijms23105354.
Chronic Kidney Disease (CKD) is a debilitating disease associated with several secondary complications that increase comorbidity and mortality. In patients with CKD, there is a significant qualitative and quantitative alteration in the gut microbiota, which, consequently, also leads to reduced production of beneficial bacterial metabolites, such as short-chain fatty acids. Evidence supports the beneficial effects of short-chain fatty acids in modulating inflammation and oxidative stress, which are implicated in CKD pathogenesis and progression. Therefore, this review will provide an overview of the current knowledge, based on pre-clinical and clinical evidence, on the effect of SCFAs on CKD-associated inflammation and oxidative stress.
慢性肾脏病（CKD）是一种使人虚弱的疾病，与多种继发性并发症相关，这些并发症会增加合并症和死亡率。在 CKD 患者中，肠道微生物组发生了显著的定性和定量改变，这也导致有益细菌代谢产物（如短链脂肪酸）的产生减少。有证据表明，短链脂肪酸在调节炎症和氧化应激方面具有有益作用，这些作用与 CKD 的发病机制和进展有关。因此，本综述将根据临床前和临床证据，概述短链脂肪酸对 CKD 相关炎症和氧化应激的影响。
